Key concepts discussed in this webinar included: - Ramifications of recent FDA in vitro DDI guidance changes to transporter study designs - Challenges from diverse compounds in otherwise ...

Multidrug resistance is a serious problem in current chemotherapy. The efflux system largely responsible for resistance in Escherichia coli contains the drug transporter, AcrB. The structures of ...

In this article, we focus on probe drugs lacking significant metabolism to highlight mechanisms of interactions of selected intestinal, hepatic and renal drug transporters (e.g., organic anion ...

Drug developers are certainly complying with the FDA’s expectations; of the 24 oral or IV small molecule drugs approved by the agency in 2012, 18 have labels that reference transporters.

Membrane drug transporters have been identified as a determinant of drug disposition in the body, potentially affecting absorption, pharmacokinetics, drug-drug interactions, and safety profiles ...

Transporter-mediated drug–drug interactions are routinely taken into account in drug development and approval. Transporter-mediated drug–drug interactions may also have beneficial effects.